Detalles de la búsqueda
1.
First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1.
Int J Clin Oncol
; 28(10): 1354-1368, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37548831
2.
Correction to: First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1.
Int J Clin Oncol
; 28(10): 1369-1370, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37684530
3.
Association between pathologic response and survival after neoadjuvant therapy in lung cancer.
Nat Med
; 30(1): 218-228, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37903504
4.
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227.
J Clin Oncol
; 41(6): 1200-1212, 2023 02 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-36223558
5.
Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1.
J Thorac Oncol
; 18(8): 1055-1069, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37146754
6.
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial.
J Thorac Oncol
; 17(2): 289-308, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34648948
Resultados
1 -
6
de 6
1
Próxima >
>>